scPharmaceuticals Inc. Enters Material Definitive Agreement
| Field | Detail |
|---|---|
| Company | Scpharmaceuticals Inc. |
| Form Type | 8-K |
| Filed Date | Sep 24, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $10.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
SCPH just signed a big deal, new financial obligations incoming.
AI Summary
On September 23, 2025, scPharmaceuticals Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware with its principal executive offices in Burlington, Massachusetts, filed this 8-K report detailing the agreement.
Why It Matters
This filing indicates a significant new financial commitment or obligation for scPharmaceuticals Inc., which could impact its financial health and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new financial risks and obligations that require careful monitoring.
Key Numbers
- 001-38293 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-5184075 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- scPharmaceuticals Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Burlington, Massachusetts (location) — Principal executive offices
- September 23, 2025 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did scPharmaceuticals Inc. enter into?
The filing states that the company entered into a 'Material Definitive Agreement' and also created a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant', but the specific details of the agreement are not provided in this excerpt.
What is the nature of the financial obligation created?
The filing indicates the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement', but the specific terms and amount of this obligation are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated September 23, 2025.
Where are scPharmaceuticals Inc.'s principal executive offices located?
The principal executive offices of scPharmaceuticals Inc. are located at 25 Mall Road, Suite 203, Burlington, Massachusetts, 01803.
What is the standard industrial classification for scPharmaceuticals Inc.?
The Standard Industrial Classification for scPharmaceuticals Inc. is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 1,083 words · 4 min read · ~4 pages · Grade level 13.3 · Accepted 2025-09-24 08:45:57
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SCPH The Nasdaq Global Se
- $10.0 million — on ("Parent") in exchange for a loan of $10.0 million by Parent to the Company. As previously
Filing Documents
- d62041d8k.htm (8-K) — 29KB
- d62041dex101.htm (EX-10.1) — 36KB
- 0001193125-25-214262.txt ( ) — 191KB
- scph-20250923.xsd (EX-101.SCH) — 3KB
- scph-20250923_lab.xml (EX-101.LAB) — 18KB
- scph-20250923_pre.xml (EX-101.PRE) — 11KB
- d62041d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Unsecured Promissory Note, dated September 23, 2025, by and between Parent and the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 24, 2025 scPharmaceuticals Inc. By: /s/ John H. Tucker Name: John H. Tucker Title: President and Chief Executive Officer